LAUSR

ABSTRACT Diacylglycerol lipase alpha (DAGLA), which catalyzes the hydrolysis of diacylglycerol to 2‐arachidonoylglycerol and free fatty acid, is required for axonal growth during the brain development and for retrograde synaptic signaling at mature synapses. So far, no information was found regarding the possible role of DAGLA in human tumorigenesis. Thus, the current study sought to clarify the contribution of DAGLA in oral squamous cell carcinomas (OSCCs) and assess the clinical possibilities for OSCC treatment. Using real‐time quantitative reverse transcription‐polymerase chain reaction, immunoblotting, and immunohistochemistry, we found a significant up‐regulation of DAGLA in OSCCs compared with normal cells and tissues both at mRNA and protein expression levels. Knockdown models in OSCC‐derived cell lines for DAGLA (siDAGLA) and treatment with a lipase inhibitor (orlistat) showed several depressed cellular functions, including cellular proliferation and migratory activities through cell‐cycle arrest at G1 phase. Furthermore, we found that DAGLA‐positive OSCC samples were correlated highly with the primary tumoral size. We concluded that DAGLA may be a key determinant in tumoral progression and might be a therapeutic target for OSCCs. HIGHLIGHTSDAGLA was up‐regulated in human oral squamous cell carcinoma (OSCC) cells compared with human normal oral keratinocytes (HNOKs).Overexpression of DAGLA in OSCCs controlled cell proliferation through cell‐cycle progression.The tumoral volume of the orlistat‐treated group was clearly smaller than that of the control group in vivo.DAGLA expression level might be a useful diagnostic indicator and a new therapeutic target for OSCCs.